As cold and flu season approaches, Canadians are facing respiratory syncytial virus (RSV), an increase in COVID-19 activity, and influenza — but also have new options to protect their health. To learn more, we spoke with Shelly Bolotin, director of the Centre for Vaccine Preventable Diseases, Shaun Morris, a pediatric infectious disease physician at the Hospital for Sick Children, and Allison McGeer, an infectious disease specialist at Toronto’s Sinai Health.
For this member spotlight, we welcome Shelly Bolotin, an associate professor at the Dalla Lana School of Public Health and in the department of laboratory medicine and pathobiology at the University of Toronto’s Temerty Faculty of Medicine. Shelly is also a scientist a Public Health Ontario and the director of the Centre for Vaccine Preventable Diseases, which aims to catalyze cutting-edge research and education that maximizes the health benefits of immunization for everyone.
According to the World Health Organization’s World Malaria Report 2022, 247 million people fell ill with malaria in 2021. In the same year, there were an estimated 619,000 deaths due to the disease, with three out of four deaths in children aged under five. With the right prevention tools and treatments, the WHO’s ambitious targets of reducing global malaria incidence and mortality rates by at least 90% by 2030 can become reality and accelerate progress towards eradication. Getting there requires innovations that have been purposely designed with implementation and impact in mind. Through their work on new diagnostics, vaccines and treatments, EPIC members are doing just that.
World TB Day: How EPIC researchers are creating better vaccines for tuberculosis and uncovering its financial burden for patients and families
Tuberculosis (TB) remains one of the world’s most deadly infectious threats and a significant global health challenge. The World Health Organization estimates that in 2021, 10.6 million people became sick with the disease and 1.6 million people died of TB, which is both preventable and curable. Learn more about how members of the University of Toronto’s Emerging and Pandemic Infections Consortium are working to tackle TB from multiple angles, from creating better vaccines to gaining a deeper understanding of TB’s financial toll on patients and families.